These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 1440852)

  • 21. Treatment of acute kidney allograft rejection with a non-mitogenic CD3 antibody.
    Meijer RT; Surachno S; Yong SL; Bemelman FJ; Florquin S; Ten Berge IJ; Schellekens PT
    Clin Exp Immunol; 2003 Sep; 133(3):485-92. PubMed ID: 12930378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease.
    Hervé P; Flesch M; Tiberghien P; Wijdenes J; Racadot E; Bordigoni P; Plouvier E; Stephan JL; Bourdeau H; Holler E
    Blood; 1992 Jun; 79(12):3362-8. PubMed ID: 1596576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A model of human anti-T-cell monoclonal antibody therapy in SCID mice engrafted with human peripheral blood lymphocytes.
    Tsuchida M; Brown SA; Tutt LM; Tan J; Seehafer DL; Harris JP; Xun CQ; Thompson JS
    Clin Transplant; 1997 Oct; 11(5 Pt 2):522-8. PubMed ID: 9361954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of acute graft-versus-host disease with monoclonal antibody OKT3. Clinical results and effect on circulating T lymphocytes.
    Gratama JW; Jansen J; Lipovich RA; Tanke HJ; Goldstein G; Zwaan FE
    Transplantation; 1984 Nov; 38(5):469-74. PubMed ID: 6388068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amelioration of acute graft-versus-host disease and re-establishment of tolerance by short-term treatment with an anti-TCR antibody.
    Maeda T; Eto M; Lin T; Nishimura Y; Kong YY; Nomoto K; Nomoto K
    J Immunol; 1994 Nov; 153(9):4311-20. PubMed ID: 7930630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiotherapy in mice with yttrium-90-labeled anti-Ly1 monoclonal antibody: therapy of established graft-versus-host disease induced across the major histocompatibility barrier.
    Vallera DA; Schmidberger H; Buchsbaum DJ; Everson P; Snover DC; Blazar BR
    Cancer Res; 1991 Apr; 51(7):1891-7. PubMed ID: 2004372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-interleukin-2 receptor monoclonal antibody (BT 563) in the treatment of severe acute GVHD refractory to systemic corticosteroid therapy.
    Cuthbert RJ; Phillips GL; Barnett MJ; Nantel SH; Reece DE; Shepherd JD; Klingemann HG
    Bone Marrow Transplant; 1992 Nov; 10(5):451-5. PubMed ID: 1464009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.
    Sao H; Kitaori K; Kasai M; Shimokawa T; Kato C; Yamanishi H; Ueda R; Morishima Y
    Int J Hematol; 1999 Jan; 69(1):27-35. PubMed ID: 10641440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients.
    Przepiorka D; Chan KW; Champlin RE; Culbert SJ; Petropoulos D; Ippoliti C; Khouri I; Huh YO; Vreisendorp H; Deisseroth AB
    Bone Marrow Transplant; 1995 Dec; 16(6):737-41. PubMed ID: 8750262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
    Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
    Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients.
    Waid TH; Lucas BA; Thompson JS; Brown SA; Munch L; Prebeck RJ; Jezek D
    Transplantation; 1992 Jan; 53(1):80-6. PubMed ID: 1531095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro analysis of donor bone marrow following monoclonal antibody treatment for the prevention of acute graft versus host disease.
    Kohler PC; Erickson C; Finlay JL; Trigg ME; Edwards B; Hong R; Hank JA; Billing R; Bozdech M; Sondel PM
    Cancer Res; 1986 Oct; 46(10):5413-8. PubMed ID: 3530439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A clinical study of haploidentical and G-CSF primed bone marrow transplantation by using CD25 for aGVHD prophylaxis].
    Ji SQ; Chen HR; Wang HX; Yan HM; Liu J; Xue M; Zhu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Oct; 10(5):447-51. PubMed ID: 12513746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of acute graft-versus-host disease after HLA-partially matched marrow transplantation with a monoclonal antibody (BMA031) against the T cell receptor. First results of a phase-I/II trial.
    Beelen DW; Graeven U; Schulz G; Grosse-Wilde H; Doxiadis I; Schaefer UW; Quabeck K; Sayer H; Schmidt CG
    Onkologie; 1988 Feb; 11(1):56-8. PubMed ID: 3283628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prophylaxis of graft-versus-host disease in identical sibling donor bone marrow transplant by anti-IL-2 receptor monoclonal antibody LO-Tact-1.
    Ferrant A; Latinne D; Bazin H; Straetmans N; Cornet A; de la Parra B; Michaux JL
    Bone Marrow Transplant; 1995 Oct; 16(4):577-81. PubMed ID: 8528175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
    Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study.
    Cahn JY; Bordigoni P; Tiberghien P; Milpied N; Brion A; Widjenes J; Lioure B; Michel G; Burdach S; Kolb HJ
    Transplantation; 1995 Nov; 60(9):939-42. PubMed ID: 7491697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [CD25 monoclonal antibody for GVHD prophylaxis in non-T-cell depleted haploidentical bone marrow transplantation for treatment of childhood leukemia].
    Chen HR; Ji SQ; Yan HM; Wang HX; Liu J; Xue M; Zhu L
    Zhonghua Er Ke Za Zhi; 2004 Apr; 42(4):294-8. PubMed ID: 15157394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Ry
    Burger DR; Parker Y; Guinta K; Lindner D
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):260-266. PubMed ID: 29128556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Removal of marrow T cells with OKT3-OKT11 monoclonal antibodies and complement to prevent acute graft-versus-host disease. A pilot study in ten patients.
    Herve P; Flesch M; Cahn JY; Racadot E; Plouvier E; Lamy B; Rozenbaum A; Noir A; Des Floris RL; Peters A
    Transplantation; 1985 Feb; 39(2):138-43. PubMed ID: 3881852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.